The efficacy and safety of gemtuzumab ozogamicin (CMA-676) in patients with acute myeloid leukemia in first relapse.

被引：0
|
作者：
Voliotis, D
Mineur, P
Dombret, H
Theobald, M
Boogaerts, M
Löwenberg, B
Sievers, EL
Larson, RA
Estey, E
Diehl, V
Stadtmauer, EA
机构：
[1] Univ Cologne, Clin Internal Med 1, Koeln, Germany
[2] Hop St Joseph, Gilly Charleroi, Belgium
[3] Hop St Louis, Paris, France
[4] Univ Clin Mainz, Mainz, Germany
[5] Univ Ziekenhuis Gasthuisberg, Louvain, Belgium
[6] Dijkzigt Ziekenhuis Rotterdam, Rotterdam, Netherlands
[7] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[8] Univ Chicago, Chicago, IL 60637 USA
[9] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[10] Univ Penn, Philadelphia, PA 19104 USA
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
424O
引用
收藏
页码：95 / 95
页数：1
相关论文
共 50 条
  • [31] Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse
    Dowell, JA
    Korth-Bradley, J
    Liu, HJ
    King, SP
    Berger, MS
    JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 41 (11): : 1206 - 1214
  • [32] Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)
    Larson, RA
    Boogaerts, M
    Estey, E
    Karanes, C
    Stadtmauer, EA
    Sievers, EL
    Mineur, P
    Bennett, JM
    Berger, MS
    Eten, CB
    Munteanu, M
    Loken, MR
    van Dongen, JJM
    Bernstein, ID
    Appelbaum, FR
    LEUKEMIA, 2002, 16 (09) : 1627 - 1636
  • [33] The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients
    L Pagano
    L Fianchi
    M Caira
    S Rutella
    G Leone
    Oncogene, 2007, 26 : 3679 - 3690
  • [34] Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)
    RA Larson
    M Boogaerts
    E Estey
    C Karanes
    EA Stadtmauer
    EL Sievers
    P Mineur
    JM Bennett
    MS Berger
    CB Eten
    M Munteanu
    MR Loken
    JJM van Dongen
    ID Bernstein
    FR Appelbaum
    Leukemia, 2002, 16 : 1627 - 1636
  • [35] Reprise: Gemtuzumab Ozogamicin for Older Patients With Acute Myeloid Leukemia
    Neuberg, Donna S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (32) : 3905 - 3906
  • [36] Use of Gemtuzumab Ozogamicin in Acute Myeloid Leukemia
    Walter, Roland B.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S95 - S96
  • [37] Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence
    Larson, RA
    Sievers, EL
    Stadtmauer, EA
    Löwenberg, B
    Estey, EH
    Dombret, H
    Theobald, M
    Voliotis, D
    Bennett, JM
    Richie, M
    Leopold, LH
    Berger, MS
    Sherman, ML
    Loken, MR
    van Dongen, JJM
    Bernstein, ID
    Appelbaum, FR
    CANCER, 2005, 104 (07) : 1442 - 1452
  • [38] Licensure of gemtuzumab ozogamicin for the treatment of selected patients 60 years of age or older with acute myeloid leukemia in first relapse
    Berger, MS
    Leopold, LH
    Dowell, JA
    Korth-Bradley, JM
    Sherman, ML
    INVESTIGATIONAL NEW DRUGS, 2002, 20 (04) : 395 - 406
  • [39] Analysis of predisposing factors for hepatic veno-occlusive disease after treatment with gemtuzumab ozogamicin (Mylotarg®, CMA-676).
    Stadtmauer, E
    Larson, R
    Sievers, E
    Estey, E
    Lowenberg, B
    Leopold, L
    Berger, M
    Dowell, J
    Wang, CP
    Appelbaum, F
    BLOOD, 2001, 98 (11) : 124A - 124A
  • [40] Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia
    Giles, F
    Estey, E
    O'Brien, S
    CANCER, 2003, 98 (10) : 2095 - 2104
12345